Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
Home > Products > Novel inhibitors

Irinotecan Hydrochloride

  Cat. No.:  DC4180   Featured
Chemical Structure
100286-90-6
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
Get Quotation Now
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
Irinotecan hydrochloride is the hydrochloride salt of a semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata.
Chemicals PropertiesBiological activity COA & MSDSRelated productsDatasheet
Cas No.: 100286-90-6
Chemical Name: Irinotecan hydrochloride
Synonyms: Irinotecan HCL;Irinotecan, Hydrochloride, Trihydrate;Irinotecan Hydrochloride;(S)-[1,4'-Bipiperidine]-1'-carboxylic acid, 4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester hydrochloride;(S)-4,11-DIETHYL-3,4,12,14-TETRAHYDRO-4-HYDROXY-3,14-DIOXO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL ESTER;TOPOTECIN HYDROCHLORIDE;CPT 11;Irinotecan;Irinotecan (hydrochloride);Irinotecan HCL Trihydrate;IRINOTECAN HCL(P);IRINOTECAN MONOHYDROCHLORIDE TRIHYDRATE;Campto;Campto hydrochloride;Camptothecin 11 hydrochloride;Camptothecin analog;CPT 11 hydrochloride;CPT-11 hydrochloride;Topotecin;Camptosar;Camptothecin 11;U 101440E;06X131E4OE;NSC616348;Irinotecan hydrochloride [USAN:JAN];DSSTox_RID_81249;DSSTox_CID_25953;DSSTox_GSID_45953;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hy...
SMILES: Cl.CCC1C2=C(N=C3C=1C=C(C=C3)OC(=O)N4CCC(CC4)N5CCCCC5)C6N(C2)C(=O)C7=C(C=6)[C@](CC)(O)C(=O)OC7
Formula: C33H39ClN4O6
M.Wt: 623.1390
Purity: 99%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: Irinotecan hydrochloride is a water soluble topoisomerase I inhibitor mainly used to treat colon cancer and rectal cancer.
Target: Topoisomerase I
In Vivo: Irinotecan (CPT-11, 5 mg/kg) significantly inhibits the growth of tumors by intratumoral injection daily for 5 days, on two consecutive weeks in rats, and such effects also occur via continuous intraperitoneal infusion by osmotic minipump into mice. However, Irinotecan (10 mg/kg) shows no effect on the growth of tumor by i.p[1]. Irinotecan (CPT-11, 100-300 mg/kg, i.p.) apparently suppresses tumor growth of HT-29 xenografts in athymic female mice by day 21. The two groups of Irinotecan (125 mg/kg) plus TSP-1 (10 mg/kg per day) or Irinotecan (150 mg/kg) in combination TSP-1 (20 mg/kg per day) are nearly equally effective and inhibit tumor growth 84% and 89%, respectively, and both are more effective than Irinotecan alone at doses of 250 and 300 mg/kg[3].
In Vitro: Irinotecan hydrochloride is a topoisomerase I inhibitor. Irinotecan inhibits the growth of LoVo and HT-29 cells, with IC50s of 15.8 ± 5.1 and 5.17 ± 1.4 μM, respectively, and induces similar amounts of cleavable complexes in both in LoVo and HT-29 cells[2]. Irinotecan suppresses the proliferation of human umbilical vein endothelial cells (HUVEC), with an IC50 of 1.3 μM[3].
Cell Assay: Exponentially growing cells are seeded in 20 cm2 dishes with an optimal cell number for each cell line (20,000 for LoVo cells, 100,000 for HT-29 cells). They are treated 2 days later with increasing concentrations of irinotecan or SN-38 for one cell doubling time (24 h for LoVo cells, 40 h for HT-29 cells). After washing with 0.15 M NaCl, the cells are further grown for two doubling times in normal medium, detached from the support with trypsin-EDTA and counted in a hemocytometer. The IC50 values are then estimated as the drug concentrations responsible for 50% growth inhibition as compared with cells incubated without drug[2].
Animal Administration: Irinotecan has been administered by intratumoral injection at 0.1 cc volume of the appropriate solution, for a doses of 5 mg/kg daily for 5 days, on two consecutive weeks, followed by a 7-days rest period, referred to as one cycle of therapy. Rats receive three cycles over a period of 8 weeks. Control animals receive 0.1 cc of sterile 0.9% sodium chloride solution by intratumoral injection in the same rule of administration as that of animals of group II[1].
References: [1]. Morales C, et al. Antitumoral effect of irinotecan (CPT-11) on an experimental model of malignant neuroectodermal tumor. J Neurooncol. 2002 Feb;56(3):219-26. [2]. Pavillard V, et al. Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines. Cancer Chemother Pharmacol. 2002 Apr;49(4):329-35. Epub 2002 Jan 30. [3]. Allegrini G, et al. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice. Cancer Chemother Pharmacol. 2004 Mar;53(3):261-6. Epub 2003 Dec 5.
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
2018-0101
2018-0101
Cat. No. Product name Field of application
DC31074 Isopropyl myristate Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868 AZ14133346 AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865 TI17 ​​TI17​​ represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816 Nisoxetine Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641 GENZ-644282 TFA salt Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325 PSMA-617 TFA PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202 Fosaprepitant free acid Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748 O4I4 O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684 ZH8667 ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646 EB-PSMA-617 EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.
X
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Site Map|Privacy PolicyCopyright © 2018-2020 All Rights Reserved. Technical Support:KuuJia